RVL Pharmaceuticals plc (NASDAQ: RVLP) Is ‘One to Watch’
For the quarter ended June 30, 2023, RVLP reported net sales of $8.3 million and operating expenses of $14.4 million, down 2% and 32%, respectively, compared to the prior year period; this strategy is designed to extend cash runway for future business development and changes in the company’s marketing mix The company’s marketing partner, Santen, has commenced the required registrational trial for UPNEEQ(R) in Japan and plans to begin the same in China in 2023 UPNEEQ(R) has strong U.S. intellectual property protection, with patents extending to 2039 RVL Pharmaceuticals launched its prescription ecommerce platform, Elevate, in July 2023, allowing providers…